Cline Darren S has filed 9 insider transactions across 3 companies since March 2023.
Most recent transaction: a grant/award of 45867 shares of Pyxis Oncology, Inc. ($PYXS) on March 24, 2026.
| Transaction Date | Company | Ticker | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| March 24, 2026 | Pyxis Oncology, Inc. | $PYXS | Cline Darren S | Not found | A | Stock Option (Right to Buy) | 45867 | $0.00 | 45,867.0000 | 62,557,386 | 9999.99% | 0.07% |
| Jan. 9, 2026 | Xenon Pharmaceuticals Inc. | $XENE | Cline Darren S | Chief Commercial Officer | A | Restricted Share Units | 20000 | $0.00 | 20,000.0000 | 79,247,976 | 9999.99% | 0.03% |
| Jan. 9, 2026 | Xenon Pharmaceuticals Inc. | $XENE | Cline Darren S | Chief Commercial Officer | A | Share Option (Right to Buy) | 40000 | $0.00 | 40,000.0000 | 79,247,976 | 9999.99% | 0.05% |
| June 23, 2025 | Xenon Pharmaceuticals Inc. | $XENE | Cline Darren S | Chief Commercial Officer | A | Share Option (Right to Buy) | 185800 | $0.00 | 185,800.0000 | 77,894,643 | 9999.99% | 0.24% |
| June 5, 2025 | PLIANT THERAPEUTICS, INC. | $PLRX | Cline Darren S | Director | A | Common Stock (Right to Buy) | 30000 | $0.00 | 30,000.0000 | 61,236,291 | 9999.99% | 0.05% |
| March 31, 2025 | Pyxis Oncology, Inc. | $PYXS | Cline Darren S | Not found | A | Stock Option (Right to Buy) | 36979 | $0.98 | 36,979.0000 | 58,445,765 | 9999.99% | 0.06% |
| June 13, 2024 | PLIANT THERAPEUTICS, INC. | $PLRX | Cline Darren S | Director | A | Common Stock (Right to Buy) | 26764 | $0.00 | 26,764.0000 | 0 | 9999.99% | 0.00% |
| March 26, 2024 | Pyxis Oncology, Inc. | $PYXS | Cline Darren S | Not found | A | Common Stock | 35219 | $0.00 | 251,405.0000 | 39,904,603 | 16.29% | 0.09% |
| March 24, 2023 | Pyxis Oncology, Inc. | $PYXS | Cline Darren S | Director | A | Common Stock | 139355 | $0.00 | 216,186.0000 | 0 | 181.38% | 0.00% |